MATERIAL SAFETY DATA SHEET
SECTION 1 - IDENTIFICATION OF PRODUCT AND COMPANY
1-866-531-8896
Pfizer Inc Emergency telephone
24 Hours
Pfizer Animal Health Hours of operation
1-800-366-5288
235 East 42nd Street Telephone
New York, NY 10017
Trade names DECTOMAX庐
Product name Doramectin Injectable Solution 10 mg/ml
Avermectin macrocyclic lactone
Chemical family
Antiparasitic (veterinary); endectocide
Therapeutic use
Amber oil
Description
SECTION 2 - COMPOSITION
Ingredient CAS Number Amount
Doramectin* 117704-25-3 1.0%
Phenol* 108-95-2 <1.0%
Ethyl oleate* 111-62-6 Trade secret
Sesame oil* 8008-74-0 Trade secret
*Hazardous
Note: Ingredient(s) indicated as hazardous have been assessed under standards
for workplace safety.
SECTION 3 - HAZARDS IDENTIFICATION
Signal word CAUTION!
Statements of hazard MAY BE HARMFUL IF SWALLOWED
POSSIBLE RISK OF HARM TO THE UNBORN CHILD
Active ingredient is not an irritant
Eye effects
Active ingredient is not a skin irritant
Skin effects
An Occupational Exposure Limit has been established for one or more of
Inhalation effects
the ingredients (see Section 8).
Ingestion effects May be harmful if swallowed (Based on components).
Animal studies with doramectin have shown a potential to cause adverse
Other potential health
effects on the fetus.
effects
07897a - Doramectin Injectable Solution 10 mg/ml Pfizer Inc.
Revision date: 09/25/03, Version: 3.0.0 Page 1 of 6
SECTION 3 - HAZARDS IDENTIFICATION ... continued
This document has been prepared in accordance with standards for
NOTE:
workplace safety, which require the inclusion of all known hazards of the
product or its ingredients regardless of the potential risk. The
precautionary statements and warnings included may not apply in all
cases. Your needs may vary depending upon the potential for exposure in
your workplace.
SECTION 4 - FIRST AID MEASURES
Skin Remove clothing and wash affected skin with soap and water. If irritation
occurs or persists, get medical attention. This material may not be
completely removed by conventional laundering. Consult professional
laundry service. Do not home launder.
Eyes Immediately flush eyes with water for at least 15 minutes. Get medical
attention.
Inhalation Remove to fresh air. If not breathing, give artificial respiration. Get
medical attention immediately.
Ingestion Get medical attention immediately. Do not induce vomiting unless directed
by medical personnel. Never give anything by mouth to an unconscious
person.
SECTION 5 - FIRE FIGHTING MEASURES
Wear approved positive pressure, self-contained breathing apparatus and
Fire fighting instructions
full protective turn out gear. Evacuate area and fight fire from a safe
distance.
Water, carbon dioxide, dry chemical or foam.
Extinguishing media
No data available
Flash point
No data available
Hazardous combustion
products
SECTION 6 - ACCIDENTAL RELEASE MEASURES
Review Sections 3, 8 and 12 before proceeding with clean up.
General
Use non-combustible material to absorb spill; then place in a suitable,
Small spill
labeled recovery container. Clean spill area thoroughly. Prevent discharge
to drains.
07897a - Doramectin Injectable Solution 10 mg/ml Pfizer Inc.
Revision date: 09/25/03, Version: 3.0.0 Page 2 of 6
SECTION 6 - ACCIDENTAL RELEASE MEASURES ... continued
Large spill Contain the source of the spill or leak if it is safe to do so. Use absorbant
material to wipe up spill and place in a sealed container for disposal. Close
container and move it to a secure holding area. Prevent discharge to
drains.
SECTION 7 - HANDLING AND STORAGE
General handling Use only in a well-ventilated area. Avoid contact with eyes. Avoid contact
with skin and clothing. Avoid breathing vapor or mist.
Storage conditions Store out of direct sunlight in a cool, well ventilated dry area. Protect from
light. Keep container tightly closed when not in use.
< 30 掳C
Temperature range
for storage
SECTION 8 - EXPOSURE CONTROLS/PERSONAL PROTECTION
Exposure limits
Compound Issuer Type OEL
Doramectin Pfizer TWA-8 HR 0.2 mg/m鲁
Phenol OSHA TWA-8 Hr 5 ppm (19 mg/m3) [skin]
NIOSH TWA-10 Hr 5 ppm (19 mg/m3) [skin]
NIOSH Ceiling 15.6 ppm (60 mg/m3) [skin]
NIOSH IDLH 250 ppm
Doramectin: CAM-JWT-93-08 (contact Pfizer for additional details)
Measurement method
Engineering controls should be used as the primary means to control
Ventilation
exposures. Good general ventilation should be sufficient to control
airborne levels. For laboratory use, handle in a lab hood.
If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an
Respiratory protection
appropriate respirator with a protection factor sufficient to control
exposures to below the OEL.
Safety glasses or goggles
Eye protection
Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in
Skin protection
both production and laboratory areas.
Rubber gloves
Hand protection
SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Liquid
Physical form
07897a - Doramectin Injectable Solution 10 mg/ml Pfizer Inc.
Revision date: 09/25/03, Version: 3.0.0 Page 3 of 6
SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES ... continued
Amber oil
Color
Mixture
Molecular weight
Mixture
Molecular formula
No data available
pH
No data available
Boiling point
Not applicable (N/A)
Melting point
No data available
Density
No data available
Vapor pressure
Insoluble
Water solubility
Freely soluble in most polar organic solvents.
Solvent solubility
SECTION 10 - STABILITY AND REACTIVITY
Stable
Reactivity
Direct sunlight, heat, sparks or open flames
Conditions to avoid
Strong oxidizers
Incompatibilities
No data available
Hazardous
decomposition
products
Will not occur
Hazardous
polymerization
SECTION 11 - TOXICOLOGY INFORMATION
The information included in this section describes the potential hazards of
Toxicology summary
the active ingredient.
Acute toxicity
Compound Type Route Species Result
Doramectin LD50 Oral Rat (M) 1000-2000 mg/kg
LD50 Oral Rat (F) 500-1000 mg/kg
LD50 Oral Rat(M) 50-100 mg/kg
LD50 Oral Rat (F) 100-200 mg/kg
Irritation Ocular Rabbit Negative
Irritation Dermal Rabbit Negative
See Acute toxicity table.
Eye
See Acute toxicity table.
Skin
07897a - Doramectin Injectable Solution 10 mg/ml Pfizer Inc.
Revision date: 09/25/03, Version: 3.0.0 Page 4 of 6
SECTION 11 - TOXICOLOGY INFORMATION ... continued
No data available
Inhalation
Ingestion See Acute toxicity table. When administered to rats in an aqueous
suspension, the LD50 ranges were 500-1000 mg/kg for females and 1000-
2000 mg/kg for males. When administered in sesame oil the acute toxicity
was greater, with LD50 ranges of 50-100 mg/kg for female rats and 100-
200 mg/kg for male rats.
No evidence of mutagenicity was observed for doramectin when tested in
Mutagenicity
vitro and in vivo in the following assays: the Ames test, the mouse
lymphoma assay, and the unscheduled DNA synthesis (UDS) assay.
Doramectin was tested in both rats and dogs. In a 3-month rat study, the
Subchronic effects
only treatment related effect noted was an increase in liver weight. In dogs
a 1-month study resulted in mydriasis, decreased food consumption and
decreased body weight. Animals receiving the high dose (4 mg/kg/day)
also exhibited tremors, salivation, ataxia, and emesis. A 3-month study in
dogs produced only dose-dependent mydriasis.
Chronic effects/ No carcinogenic data available. However, the carcinogenic potential of a
carcinogenicity structurally related avermectin, abamectin, has been investigated in
rodents. No evidence of carcinogenicity was seen in these studies.
None of the components of this formulation are listed as a carcinogen by
Carcinogen status
IARC, NTP or OSHA.
No reproductive effects were observed in a two-generation oral toxicity
Reproductive effects
study in rats.
Embryomortality was seen in mice but not in rats treated with doramectin.
Teratogenicity
Delayed pubic bone ossification was seen in rabbits. Additional fetal
anomalies seen in rabbits at higher doses were thought to be due to
maternal toxicity.
This material has been shown in rats to be excreted in milk and, as a result,
At increased risk from
to cause toxicity in young pups; nursing mothers should exercise caution
exposure
regarding exposure.
SECTION 12 - ECOLOGICAL INFORMATION
In the environment, the active ingredient in this formulation is expected to
Environmental overview
bind tightly to soil or sediment and not readily desorb. It is unlikely to reach
groundwater and is also biodegradable by soil microflora. Harmful effects
to aquatic organisms could occur.
See aquatic toxicity data, below.
Bioaccumulation and
toxicity:
07897a - Doramectin Injectable Solution 10 mg/ml Pfizer Inc.
Revision date: 09/25/03, Version: 3.0.0 Page 5 of 6
SECTION 12 - ECOLOGICAL INFORMATION ... continued
Aquatic toxicity
Compound Type Species Result
Doramectin EC50/48h Daphnia magna 0.1 ppb
LC50/96h Bluegill Sunfish 11 ppb
LC50/96h Rainbow Trout 5.1 ppb
MIC/24-48h Aspergillus niger 600 mg/l
MIC/24-48h Clostridium 40 mg/l
perfringens
MIC/14days Green Algae <1 mg/l
MIC/24-72h Nostoc 60 mg/l
SECTION 13 - DISPOSAL INFORMATION
Incineration is the recommended method of disposal for this material.
Disposal procedure
Observe all local and national regulations when disposing of this mixture.
SECTION 14 - TRANSPORTATION INFORMATION
Not regulated for transport under USDOT, EUADR, IATA, or IMDG
General shipping
regulations.
instructions
SECTION 15 - REGULATORY INFORMATION
Dangerous for the Environment
EU Classification
None required
EU Labelling
R52/53 - Harmful to aquatic organisms, may cause long-term adverse
Risk phrases
effects in the aquatic environment.
S57 - Use appropriate containment to avoid environmental contamination.
Safety phrases
Class D, Division 2, Subdivision A
Canadian WHMIS
SECTION 16 - OTHER
Disclaimer Pfizer Inc believes that the information contained in this Material
Safety Data Sheet is accurate, and while it is provided in good faith, it
is without a warranty of any kind, expressed or implied.
07897a - Doramectin Injectable Solution 10 mg/ml Pfizer Inc.
Revision date: 09/25/03, Version: 3.0.0 Page 6 of 6
|